Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes
Revolution Medicines, a clinical-stage oncology firm focusing on RAS-addicted cancer therapies, announced an increase in its concurrent public offerings to raise approximately $2 billion. The offerings include about 10.56 million shares of common stock priced at $142 per share (up from $750 million to $1.5 billion) and $500 million in 0.5% converti…